T7814

Alloxan Monohydrate is a diabetogenic agent that acts as a proteasome inhibitor and induces diabetes in experimental animals by damaging the insulin-secreting β-cells in the pancreas. It is commonly used to establish diabetes models.

ZINC00784494 is a selective inhibitor of LCN2 (lipocalin-2), which inhibits cancer cell proliferation and reduces AKT phosphorylation levels, prevents the transition of the cell cycle from the G0/G1 phase to the S phase, and promotes apoptosis. It can be used for the study of inflammatory breast cancer (IBC).

ELOVL6-IN-1 is a potent, selective, and orally active inhibitor of ELOVL6, exhibiting dose-dependent inhibition of mouse ELOVL6 with an IC50 of 0.350 μM and acting as a noncompetitive inhibitor with respect to malonyl-CoA (Ki=994 nM) and palmitoyl-CoA [1].

LFHP-1c is a novel PGAM5 inhibitor that shows neuroprotective activity in an ischemic stroke model, preventing BBB destruction after transient middle cerebral artery occlusion (tMCAO) in rats.LFHP-1c can be used to study cerebral ischemic stroke.

DC-BPi-11 hydrochloride is a BPTF (bromodomain PHD finger transcription factor) inhibitor with an IC50 value of 698 nM, demonstrating significant anti-proliferative effects on leukemia cells [1].

(R)-VX-11e is an isomer of VX-11e, a potent and selective ERK2 inhibitor with potential to inhibit tumor growth.

NCGC00138783 TFA acts as a selective inhibitor of the CD47/SIRPα axis, exhibiting an inhibitory concentration (IC50) of 50 μM. This compound effectively obstructs the interaction between CD47 and SIRPα [1] [2].

HDAC10-IN-2 hydrochloride (compound 10c) is a highly potent and selective HDAC10 inhibitor with an IC50 of 20 nM, influencing autophagy in aggressive FLT3-ITD positive acute myeloid leukemia cells [1].

NaPi2b-IN-2 (compound 5) is a potent inhibitor of the sodium-dependent transport protein 2b (SLC34A2, NaPi2b), with an IC50 of 38 nM against human NaPi2b. It holds potential for hyperphosphatemia research [1].

TP-5801 TFA is an orally active inhibitor of TNK1, a non-receptor tyrosine kinase, with an IC50 of 1.40 nM, demonstrating anti-tumor activity [1].

BAY-252 is a potent inhibitor of branched-chain amino acid transaminases 1 (BCAT1) and BCAT2, with IC50 of 2 μM for both enzymes. In addition to its inhibitory properties, BAY-252 serves as a chemical probe in cancer research, aiding in the investigation of metabolic pathways involving branched-chain amino acids.